Protox Therapeutics Inc T.PRX

SEPTEMBER IS THE MONTH

[cabbieJBJ]

Can anyone else feel the PRX earth moving underneath us?  Sure seems like it to me.

 

The 12-month follow up will provide direction for PRX.  If continuing positive on outcomes and continuing absence of side effects, we’ll see a pleasant and maybe even a substantial bump. 

The Phase 2 Triumph study should complete its enrollment with results pending in Q4; and announcement of the completion of the enrollment, coupled with the 12-month follow up could give another bump.

 

Licensing deals are just around the corner if all is positive; on the other hand, the big boys could be circling for a buyout based upon BPH near term commercialization AND (I suspect) partial positive result on prostate cancer and brain cancer.  Cancer is the hot topic in the biotech world.  Valuations of a small Canadian company will be substantially less that in the USA, so there may be a first mover advantage to a company that can put together a cash or cash + Stock package in the $3 to $5 range.

 

How do others feel?

 

Lets get the discussion going!

 

Thx, jb

[treefort]

Hey cabbie,$0$0$0$0I just stumbled on PRX, and am very interested. It seems to have a lot of potential. What is the 12 month follow up that you are talking about?$0

[cabbieJBJ]

they did open label dosing studies and others I think for BPH.  They have been following up on the study population and the study group continues to show positive results from the intial treatment; and no side effects.The 12 month follow up is due momentarily.If you read the Protox press releases, they will fill in more detail for you.Please let know what you think.Cheers, jb

[bioboy10]

The data to be presented in Sept is the 12 month out data from phase 2 study conducted last year.  It will determine the saftey and effectiveness of the BHP drug out 12 months. This will be an important milestone. If the IPSS score on the 12 month follow-up is still good then we can assume that the next study will provide decent results against the pacebo out to 12 months.Placebo will only

[cabbieJBJ]

I agree that management has been too passive in marketing the story.  They should have done a much better job.  Hope they utilize the upcoming results to really hammer home the story.The dilution does not overly concern me as they needed capital for the development program.  It was expensive, but often the money to get over the finish line is the most expensive.Maybe the 12

[bioboy10]

Cabbie,If the 12 month follow-up and blind study are sooo successful. There will be no choice but for something big to happen .. If the price lags then ther will be a take out offer ?. management will be under pressure to  get a deal done with someone. Money will be running out they would need to partner up for phase 3.The average uptick on biostocks when they have reaced there critical

[cabbieJBJ]

Bioboy - I couldn't agree more with your analysis.  The next 4 months will tell the tale.  I'm long with my 60K shares.BTW, if you're interested in stepping out of biotech, take a look at Wi-lan (WIN:T).  It's a tech patent licensing play.  Cheers, jb